IMUGENE LIMITED - Announcements

0.00%

26.5¢

Market Cap $76.45M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Announcements

Filter Results

All Price Sensitive Only

IMU	Release of Shares from Escrow		01/09/22	130.41KB	Share
IMU	Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA	PRICE SENSITIVE	01/09/22	232.91KB	Share
IMU	Environmental Social and Governance (ESG) Report		31/08/22	496.25KB	Share
IMU	Corporate Governance Statement		31/08/22	203.19KB	Share
IMU	Appendix 4G		31/08/22	262.63KB	Share
IMU	Annual Report and Appendix 4E	PRICE SENSITIVE	31/08/22	2.3MB	Share
IMU	FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC	PRICE SENSITIVE	10/08/22	196.13KB	Share
IMU	Imugene Presents New PD1-Vaxx Data at the 2022 WCLC	PRICE SENSITIVE	08/08/22	356.21KB	Share
IMU	Application for quotation of securities - IMU		05/08/22	26.49KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/22	837.24KB	Share
IMU	Notification regarding unquoted securities - IMU		21/07/22	33.86KB	Share
IMU	Application for quotation of securities - IMU		21/07/22	25.66KB	Share
IMU	Imugene appoints experienced life sciences CFO Mike Tonroe		18/07/22	190.01KB	Share
IMU	IMU to Present New PD1-Vaxx Data at the WCLC 2022		13/07/22	189.19KB	Share
IMU	Appointment of Dr Sharon Yavrom as Clinical Scientist		01/07/22	186.32KB	Share
IMU	Investor Webinar - Final HER-Vaxx Overall Survival Results		27/06/22	186.5KB	Share
IMU	Final HER-Vaxx Phase 2 Trial Overall Survival Results	PRICE SENSITIVE	27/06/22	224.59KB	Share
IMU	Change of Director's Interest Notice - CW		14/06/22	172.19KB	Share
IMU	Change of Director's Interest Notice - LR		09/06/22	370.15KB	Share
IMU	Notice Under Section 708A		08/06/22	126.16KB	Share
IMU	Application for quotation of securities - IMU		08/06/22	36.39KB	Share
IMU	IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD		01/06/22	121.37KB	Share
IMU	IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022		31/05/22	118.67KB	Share
IMU	IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT		27/05/22	118.35KB	Share
IMU	Letter to Shareholders		23/05/22	122.24KB	Share
IMU	IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL	PRICE SENSITIVE	18/05/22	230.78KB	Share
IMU	IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON	PRICE SENSITIVE	10/05/22	116.77KB	Share
IMU	Response to ASX Query	PRICE SENSITIVE	09/05/22	305.29KB	Share
IMU	Clarification Announcement	PRICE SENSITIVE	03/05/22	165.86KB	Share
IMU	Pause in Trading	PRICE SENSITIVE	03/05/22	115.68KB	Share
IMU	Termination of Supply Agreement	PRICE SENSITIVE	02/05/22	104.46KB	Share
IMU	Application for quotation of securities - IMU		29/04/22	29.09KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/04/22	3.08MB	Share
IMU	First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc		13/04/22	126.81KB	Share
IMU	Release of Securities from Escrow		12/04/22	93.88KB	Share
IMU	Application for quotation of securities - IMU		01/04/22	29.08KB	Share
IMU	Dose Escalation in Phase 1 Clinical Trial of CHECKvacc	PRICE SENSITIVE	24/03/22	109.98KB	Share
IMU	Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia	PRICE SENSITIVE	23/03/22	110.26KB	Share
IMU	Investor webinar Imugene & Merck collaboration		15/03/22	122.48KB	Share
IMU	Imugene HER-Vaxx Clinical Trial Collaboration with Merck	PRICE SENSITIVE	15/03/22	151.02KB	Share
IMU	Application for quotation of securities - IMU		04/03/22	29.06KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	5.61MB	Share
IMU	Science Series CHECKvacc		23/02/22	7MB	Share
IMU	Notice Under Section 708A		11/02/22	158.95KB	Share
IMU	Application for quotation of securities - IMU		11/02/22	32.03KB	Share
IMU	Change of Director's Interest Notice - JE		09/02/22	189.22KB	Share
IMU	Notification regarding unquoted securities - IMU		07/02/22	29.06KB	Share
IMU	Notice Under Section 708A		04/02/22	160.78KB	Share
IMU	Application for quotation of securities - IMU		04/02/22	32.39KB	Share
IMU	Application for quotation of securities - IMU		04/02/22	37.59KB	Share
IMU	BPAY or EFT Process for IMUOC & IMUOD Option Holders		04/02/22	914.6KB	Share
IMU	Notification regarding unquoted securities - IMU		01/02/22	35.75KB	Share
IMU	Appointment of Dr Steven Cha as Chief Medical Officer		01/02/22	81.25KB	Share
IMU	Issue of Options under the Employee Share Option Plan		31/01/22	97.09KB	Share
IMU	Oncolytic Virotherapy CF33 Patent Granted in Japan	PRICE SENSITIVE	31/01/22	119.32KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	3.82MB	Share
IMU	PD1-Vaxx Clinical Trial Supply Agreement with Roche	PRICE SENSITIVE	28/01/22	107.17KB	Share
IMU	HER-Vaxx Immunotherapy Patent Granted in Europe	PRICE SENSITIVE	28/01/22	123.17KB	Share
IMU	Application for quotation of securities - IMU		21/01/22	25.65KB	Share
IMU	Retirement of Chief Medical Officer		21/01/22	82.93KB	Share
IMU	Application for quotation of securities - IMU		14/01/22	28.44KB	Share
IMU	Release of Securities from Escrow		10/01/22	74.52KB	Share
IMU	Imugene Receives $6.54 million R&D Tax Incentive	PRICE SENSITIVE	06/01/22	83.04KB	Share
IMU	South Korea HERVaxx Patent Grant	PRICE SENSITIVE	06/01/22	94.04KB	Share
IMU	Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx	PRICE SENSITIVE	04/01/22	96.13KB	Share
IMU	Imugene adds industry leaders to senior management team		04/01/22	82.64KB	Share
IMU	Notice Under Section 708A		23/12/21	159.41KB	Share
IMU	Notification regarding unquoted securities - IMU		23/12/21	30.19KB	Share
IMU	Application for quotation of securities - IMU		23/12/21	29.09KB	Share
IMU	Change of Director's Interest Notice - CW		20/12/21	267.06KB	Share
IMU	Appendix 2A and IMUOB Option Underwriting Agreement		20/12/21	521.06KB	Share
IMU	Change in substantial holding - PH		15/12/21	222.31KB	Share
IMU	Imugene HER-Vaxx Immunotherapy Patent Allowed in China		14/12/21	146.21KB	Share
IMU	Change of Director's Interest Notice - PH		13/12/21	349.99KB	Share
IMU	FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX	PRICE SENSITIVE	13/12/21	177.59KB	Share
IMU	FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA	PRICE SENSITIVE	13/12/21	127.52KB	Share
IMU	Appendix 2A		10/12/21	364.47KB	Share
IMU	Change in Joint Company Secretary		08/12/21	93.96KB	Share
IMU	Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc	PRICE SENSITIVE	07/12/21	158.38KB	Share
IMU	Appendix 2A		06/12/21	364.16KB	Share
IMU	S&P DJI Announces December 2021 Quarterly Rebalance	PRICE SENSITIVE	03/12/21	92.25KB	Share
IMU	Appendix 2A		26/11/21	364.09KB	Share
IMU	Results of Meeting Percentages		23/11/21	157.69KB	Share
IMU	Final Director's Interest Notice (AH)		22/11/21	269.7KB	Share
IMU	Ceasing to be a Director		22/11/21	83.35KB	Share
IMU	Change of Director's Interest Notice (AH)		22/11/21	184.15KB	Share
IMU	Results of Meeting		19/11/21	506.9KB	Share
IMU	Application for quotation of securities - IMU		19/11/21	29.08KB	Share
IMU	AGM Presentation		19/11/21	4.73MB	Share
IMU	Notice Under Section 708A		16/11/21	161.07KB	Share
IMU	Application for quotation of securities - IMU		16/11/21	26.92KB	Share
IMU	Clinical Trial Supply Agreement with Merck KGaA and Pfizer	PRICE SENSITIVE	16/11/21	124.99KB	Share
IMU	Application for quotation of securities - IMU		12/11/21	29.08KB	Share
IMU	Eureka Strategic Collaboration (supplementary announcement)		09/11/21	121.8KB	Share
IMU	Application for quotation of securities - IMU		05/11/21	29.08KB	Share
IMU	Investor Presentation Imugene Eureka Therapeutics	PRICE SENSITIVE	01/11/21	2.22MB	Share
IMU	Investor webinar Imugene & Eureka Therapeutics Collaboration		01/11/21	115.65KB	Share
IMU	Imugene and Eureka Therapeutics onCARlytics Collaboration	PRICE SENSITIVE	01/11/21	145.54KB	Share
IMU	Application for quotation of securities - IMU		29/10/21	29.08KB	Share
IMU	Application for quotation of securities - IMU		25/10/21	29.08KB	Share

IMU Release of Shares from Escrow
01/09/22		130.41KB	Share
IMU Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
01/09/22	PRICE SENSITIVE	232.91KB	Share
IMU Environmental Social and Governance (ESG) Report
31/08/22		496.25KB	Share
IMU Corporate Governance Statement
31/08/22		203.19KB	Share
IMU Appendix 4G
31/08/22		262.63KB	Share
IMU Annual Report and Appendix 4E
31/08/22	PRICE SENSITIVE	2.3MB	Share
IMU FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC
10/08/22	PRICE SENSITIVE	196.13KB	Share
IMU Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
08/08/22	PRICE SENSITIVE	356.21KB	Share
IMU Application for quotation of securities - IMU
05/08/22		26.49KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
25/07/22	PRICE SENSITIVE	837.24KB	Share
IMU Notification regarding unquoted securities - IMU
21/07/22		33.86KB	Share
IMU Application for quotation of securities - IMU
21/07/22		25.66KB	Share
IMU Imugene appoints experienced life sciences CFO Mike Tonroe
18/07/22		190.01KB	Share
IMU IMU to Present New PD1-Vaxx Data at the WCLC 2022
13/07/22		189.19KB	Share
IMU Appointment of Dr Sharon Yavrom as Clinical Scientist
01/07/22		186.32KB	Share
IMU Investor Webinar - Final HER-Vaxx Overall Survival Results
27/06/22		186.5KB	Share
IMU Final HER-Vaxx Phase 2 Trial Overall Survival Results
27/06/22	PRICE SENSITIVE	224.59KB	Share
IMU Change of Director's Interest Notice - CW
14/06/22		172.19KB	Share
IMU Change of Director's Interest Notice - LR
09/06/22		370.15KB	Share
IMU Notice Under Section 708A
08/06/22		126.16KB	Share
IMU Application for quotation of securities - IMU
08/06/22		36.39KB	Share
IMU IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD
01/06/22		121.37KB	Share
IMU IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022
31/05/22		118.67KB	Share
IMU IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT
27/05/22		118.35KB	Share
IMU Letter to Shareholders
23/05/22		122.24KB	Share
IMU IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
18/05/22	PRICE SENSITIVE	230.78KB	Share
IMU IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
10/05/22	PRICE SENSITIVE	116.77KB	Share
IMU Response to ASX Query
09/05/22	PRICE SENSITIVE	305.29KB	Share
IMU Clarification Announcement
03/05/22	PRICE SENSITIVE	165.86KB	Share
IMU Pause in Trading
03/05/22	PRICE SENSITIVE	115.68KB	Share
IMU Termination of Supply Agreement
02/05/22	PRICE SENSITIVE	104.46KB	Share
IMU Application for quotation of securities - IMU
29/04/22		29.09KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
22/04/22	PRICE SENSITIVE	3.08MB	Share
IMU First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc
13/04/22		126.81KB	Share
IMU Release of Securities from Escrow
12/04/22		93.88KB	Share
IMU Application for quotation of securities - IMU
01/04/22		29.08KB	Share
IMU Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
24/03/22	PRICE SENSITIVE	109.98KB	Share
IMU Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
23/03/22	PRICE SENSITIVE	110.26KB	Share
IMU Investor webinar Imugene & Merck collaboration
15/03/22		122.48KB	Share
IMU Imugene HER-Vaxx Clinical Trial Collaboration with Merck
15/03/22	PRICE SENSITIVE	151.02KB	Share
IMU Application for quotation of securities - IMU
04/03/22		29.06KB	Share
IMU Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	5.61MB	Share
IMU Science Series CHECKvacc
23/02/22		7MB	Share
IMU Notice Under Section 708A
11/02/22		158.95KB	Share
IMU Application for quotation of securities - IMU
11/02/22		32.03KB	Share
IMU Change of Director's Interest Notice - JE
09/02/22		189.22KB	Share
IMU Notification regarding unquoted securities - IMU
07/02/22		29.06KB	Share
IMU Notice Under Section 708A
04/02/22		160.78KB	Share
IMU Application for quotation of securities - IMU
04/02/22		32.39KB	Share
IMU Application for quotation of securities - IMU
04/02/22		37.59KB	Share
IMU BPAY or EFT Process for IMUOC & IMUOD Option Holders
04/02/22		914.6KB	Share
IMU Notification regarding unquoted securities - IMU
01/02/22		35.75KB	Share
IMU Appointment of Dr Steven Cha as Chief Medical Officer
01/02/22		81.25KB	Share
IMU Issue of Options under the Employee Share Option Plan
31/01/22		97.09KB	Share
IMU Oncolytic Virotherapy CF33 Patent Granted in Japan
31/01/22	PRICE SENSITIVE	119.32KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	3.82MB	Share
IMU PD1-Vaxx Clinical Trial Supply Agreement with Roche
28/01/22	PRICE SENSITIVE	107.17KB	Share
IMU HER-Vaxx Immunotherapy Patent Granted in Europe
28/01/22	PRICE SENSITIVE	123.17KB	Share
IMU Application for quotation of securities - IMU
21/01/22		25.65KB	Share
IMU Retirement of Chief Medical Officer
21/01/22		82.93KB	Share
IMU Application for quotation of securities - IMU
14/01/22		28.44KB	Share
IMU Release of Securities from Escrow
10/01/22		74.52KB	Share
IMU Imugene Receives $6.54 million R&D Tax Incentive
06/01/22	PRICE SENSITIVE	83.04KB	Share
IMU South Korea HERVaxx Patent Grant
06/01/22	PRICE SENSITIVE	94.04KB	Share
IMU Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
04/01/22	PRICE SENSITIVE	96.13KB	Share
IMU Imugene adds industry leaders to senior management team
04/01/22		82.64KB	Share
IMU Notice Under Section 708A
23/12/21		159.41KB	Share
IMU Notification regarding unquoted securities - IMU
23/12/21		30.19KB	Share
IMU Application for quotation of securities - IMU
23/12/21		29.09KB	Share
IMU Change of Director's Interest Notice - CW
20/12/21		267.06KB	Share
IMU Appendix 2A and IMUOB Option Underwriting Agreement
20/12/21		521.06KB	Share
IMU Change in substantial holding - PH
15/12/21		222.31KB	Share
IMU Imugene HER-Vaxx Immunotherapy Patent Allowed in China
14/12/21		146.21KB	Share
IMU Change of Director's Interest Notice - PH
13/12/21		349.99KB	Share
IMU FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX
13/12/21	PRICE SENSITIVE	177.59KB	Share
IMU FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA
13/12/21	PRICE SENSITIVE	127.52KB	Share
IMU Appendix 2A
10/12/21		364.47KB	Share
IMU Change in Joint Company Secretary
08/12/21		93.96KB	Share
IMU Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
07/12/21	PRICE SENSITIVE	158.38KB	Share
IMU Appendix 2A
06/12/21		364.16KB	Share
IMU S&P DJI Announces December 2021 Quarterly Rebalance
03/12/21	PRICE SENSITIVE	92.25KB	Share
IMU Appendix 2A
26/11/21		364.09KB	Share
IMU Results of Meeting Percentages
23/11/21		157.69KB	Share
IMU Final Director's Interest Notice (AH)
22/11/21		269.7KB	Share
IMU Ceasing to be a Director
22/11/21		83.35KB	Share
IMU Change of Director's Interest Notice (AH)
22/11/21		184.15KB	Share
IMU Results of Meeting
19/11/21		506.9KB	Share
IMU Application for quotation of securities - IMU
19/11/21		29.08KB	Share
IMU AGM Presentation
19/11/21		4.73MB	Share
IMU Notice Under Section 708A
16/11/21		161.07KB	Share
IMU Application for quotation of securities - IMU
16/11/21		26.92KB	Share
IMU Clinical Trial Supply Agreement with Merck KGaA and Pfizer
16/11/21	PRICE SENSITIVE	124.99KB	Share
IMU Application for quotation of securities - IMU
12/11/21		29.08KB	Share
IMU Eureka Strategic Collaboration (supplementary announcement)
09/11/21		121.8KB	Share
IMU Application for quotation of securities - IMU
05/11/21		29.08KB	Share
IMU Investor Presentation Imugene Eureka Therapeutics
01/11/21	PRICE SENSITIVE	2.22MB	Share
IMU Investor webinar Imugene & Eureka Therapeutics Collaboration
01/11/21		115.65KB	Share
IMU Imugene and Eureka Therapeutics onCARlytics Collaboration
01/11/21	PRICE SENSITIVE	145.54KB	Share
IMU Application for quotation of securities - IMU
29/10/21		29.08KB	Share
IMU Application for quotation of securities - IMU
25/10/21		29.08KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 26.5¢		Change 0.000(0.00%)		Mkt cap ! $76.45M

Open	High	Low	Value	Volume
26.5¢	27.0¢	25.5¢	$513.0K	1.955M

Buyers (Bids)

No.	Vol.	Price($)
6	73813	26.5¢

Sellers (Offers)

Price($)	Vol.	No.
27.0¢	132126	9

View Market Depth

No.	Vol.	Price($)
4	21741	0.265
9	463455	0.260
28	603577	0.255
45	695939	0.250
15	185955	0.245

Price($)	Vol.	No.
0.270	132126	9
0.275	123184	7
0.280	104829	6
0.285	138065	7
0.290	206012	9

Last trade - 16.11pm 11/08/2025 (20 minute delay)


Last 26.5¢		Change 0.000 ( 0.11 %)
Open	High	Low	Volume
26.0¢	27.0¢	25.5¢	446487
Last updated 15.59pm 11/08/2025 ?

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories